More on RX
Data
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $21.98 |
|
|||
| Open | $14.68 | ||||
| 52 Wk High | $21.99 | ||||
| 52 Wk Low | $11.12 | ||||
| Day High | $21.98 | ||||
| Day Low | $21.98 | ||||
| P/E | 15.48 | ||||
| EPS | $1.42 | ||||
| Volume | 1,100 | ||||
- BioSyent receives Health Canada approval for levothyroxine oral solution
- BioSyent Announces Health Canada Approval of Thyconvi™ (levothyroxine oral solution)
- BioSyent Declares Second Quarter 2026 Dividend
- BioSyent Releases Financial Results for First Quarter 2026
- BioSyent Schedules First Quarter 2026 Earnings Release for May 14, 2026
- BioSyent to Present at 2026 Bloom Burton & Co. Healthcare Investor Conference
- FeraMAX is Canada's Top-Ranked Iron Supplement for 11 Consecutive Years
- BioSyent Announces Grant of Restricted Share Units
- BioSyent Releases Financial Results for Fourth Quarter and Full Year 2025
- BioSyent Schedules Fourth Quarter and Full Year 2025 Earnings Release for March 19, 2026
Entities mentioned with RX
- Earnings | View Related Stories »
- Dividend | View Related Stories »
- Definitive Agreement | View Related Stories »
- Raymond James | View Related Stories »
- Morgan Stanley | View Related Stories »
- Warren Buffett | View Related Stories »
- Citi | View Related Stories »
- RBC Capital | View Related Stories »
- Show More...
